Incoming CHA Biotech CEO Choi Suk-yoon / Courtesy of CHA Biotech

CHA Biotech will appoint Choi Suk-yoon, former Meritz Securities adviser, as its new vice chair and CEO in its upcoming shareholder and board meeting on Monday, the cell and gene therapy firm said Friday.

Choi is an investment banking expert with over 40 years of experience. He previously served as the country head for the Royal Bank of Scotland Korea and Goldman Sachs from 2007 to 2015. He was also an adjunct professor at Seoul National University. In 2018, he was appointed president of Meritz Fire & Marine, and in 2021, he became an adviser to Meritz Securities.

CHA Biotech also appointed Han Ki-won, former commissioner of Invest KOREA, as the head of global business. Han is a financial expert who worked for Japan's Daiwa Securities for 25 years.

The biotech company expects Han to spearhead its hospital business in Japan and expand its presence in the Asian health care market.